Tata Group
 
 
Dr M. Vidyasagar
TCS links

print this page
  TCS > articles
 
TCS moves into bioinformatics

Bioinformatics, the science of developing computer databases and algorithms to facilitate and expedite biological research, has come on as the next big opportunity for the Indian software industry. The latest player in the Indian bioinformatics market is the country’s largest information technology company, Tata Consultancy Services (TCS).

Based at the company’s Advanced Technology Centre (ATC) in Hyderabad and headed by Dr M. Vidyasagar, executive vice-president, TCS, the bioinformatics practice will enable TCS to provide services such as automated genome analysis, protein structure prediction and high throughput molecular modelling, rational drug design, and creation and integration of relational databases from proprietary, unstructured pharmaceutical and clinical data.

Other services that the ATC is gearing up to provide include the following:

  • Development of customised software for pharmaceutical, biomedical and biotechnology companies;
  • Analysis of the results of various biological experiments in genomics and proteomics;
  • Searchable and user-friendly databases;
  • Prediction of gene function, protein-protein interaction;
  • Customised crystal structure solutions.

TCS has, for this venture, entered into a collaborative research agreement with the Centre for DNA Fingerprinting and Diagnostics (CDFD), a research and development laboratory under the Indian government’s Department of Biotechnology.

Under the agreement, CDFD, with its expertise in computational biology and modern recombinant DNA techniques, will train personnel in biology, while TCS will train them in IT. The first batch of 20 recruits for this initiative was culled from a field of over 2,000 applicants.

The company’s first priority, according to Dr Vidyasagar, is to train the new recruits in both biosciences and IT for about nine months, and transform them into ‘billable’ employees. “It will take at least another year for things to evolve fully,” he says.

For now the entry into bioinformatics reflects the company’s strategy to gain early-mover advantage, just as it did in the software industry back in the 1960s.

Netscribes / Ganesh Ramamoorthy

top of the page